by Clinical Neuropsychologist | Tuesday, December 31, 2024 | Dementia
Abstract INTRODUCTION Aggregation of hyperphosphorylated tau (tauopathy) is associated with cognitive impairment in patients with Alzheimer’s disease (AD). In AD, a metabolic shift due to the Warburg effect results in increased lactate production. Lactate can...
by Clinical Neuropsychologist | Tuesday, December 31, 2024 | Dementia
Abstract Blood-based biomarkers (BBBMs) for Alzheimer’s disease (AD) have the potential to revolutionize the detection and management of cognitive impairment. AD BBBMs are not currently recommended for use in primary care but may soon be as research demonstrates...
by Clinical Neuropsychologist | Sunday, December 29, 2024 | Dementia
Abstract INTRODUCTION The choroid plexus (CP) may play a crucial role in brain degeneration. We aim to assess whether CP cysts (CPCs), defined using ultra-high field magnetic resonance imaging (MRI), relate to aging and neurodegeneration. METHODS We used...
by Clinical Neuropsychologist | Sunday, December 29, 2024 | Dementia
Abstract INTRODUCTION Alzheimer’s disease (AD) is now diagnosed biologically. Since subjective cognitive decline (SCD) may indicate preclinical AD, assessing AD-biomarkers is crucial. We investigated cognitive and neurodegenerative trajectories in SCD over 24...
by Clinical Neuropsychologist | Sunday, December 29, 2024 | Dementia
Abstract INTRODUCTION Type 2 diabetes increases the risk of Alzheimer’s disease (AD) dementia. Insulin signaling dysfunction exacerbates tau protein phosphorylation, a hallmark of AD pathology. However, the comprehensive impact of diabetes on patterns of...
by Clinical Neuropsychologist | Sunday, December 29, 2024 | Dementia
Alzheimer’s &Dementia, EarlyView. If you do not see content above, kindly GO TO SOURCE. Not all publishers encode content in a way that enables republishing at Neuro.vip. This post is Copyright: Anthony E. Lang, Günter U. Höglinger, Charles H. Adler, Daniela...
